Skip to main content

Puma Biotechnology (PBYI) Receives a Sell from Barclays

Tipranks - Tipranks - Sat Nov 8, 2025

In a report released today, Gena Wang from Barclays maintained a Sell rating on Puma Biotechnology, with a price target of $2.00.

Meet Your ETF AI Analyst

Wang covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Cytokinetics, and Intellia Therapeutics. According to TipRanks, Wang has an average return of 4.8% and a 43.80% success rate on recommended stocks.

Currently, the analyst consensus on Puma Biotechnology is a Moderate Sell with an average price target of $3.50.

See the top stocks recommended by analysts >>

Based on Puma Biotechnology’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $52.44 million and a net profit of $5.86 million. In comparison, last year the company earned a revenue of $47.08 million and had a GAAP net loss of $4.53 million

Read More on PBYI:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).